Trevi Therapeutics, Inc.

NASDAQ•TRVI

CEO: Ms. Jennifer L. Good

セクター: Healthcare

業種: Biotechnology

上場日: 2019-05-07

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

連絡先情報

195 Church Street, 16th Floor, New Haven, CT, 06510, United States

203-304-2499

www.trevitherapeutics.com

時価総額

$1.96B

PER (TTM)

-51.8

18.2

配当利回り

52週高値

$15.76

52週安値

$5.38

52週レンジ

95%

順位62Top 92.6%

1.9

F-Score

改良版 Piotroski 分析

9年ファンダメンタル

弱い • 1.9 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2017-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.06+0.00%

直近4四半期の推移

フリーCF

$5.85M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Net Loss Narrows Significantly Net loss decreased $5.2M to $42.8M for 2025, reflecting reduced R&D spending versus prior year.

Strong Cash Position Maintained Cash and marketable securities reached $188.3M by year-end 2025, funding operations into 2028.

Positive Cough Trial Results Phase 2b CORAL trial achieved primary endpoint showing significant 24-hour cough frequency reduction.

Phase 3 Trials Scheduled FDA alignment secured; first pivotal Phase 3 trial for IPF-related cough set to initiate Q2 2026.

リスク要因

Continued Operating Losses Expected Significant losses incurred since inception; substantial additional capital required to fund operations beyond 2028.

Sole Product Candidate Dependency Business success entirely dependent on Haduvio development, approval, and commercialization success across indications.

Clinical Trial Design Uncertainty Trial outcomes are uncertain; regulatory changes or enrollment difficulties could delay approval or increase costs.

Opioid Class Label Warning Nalbuphine carries opioid class warning; potential restrictive marketing/distribution regulations could harm profitability.

見通し

Initiate Pivotal Phase 3 Studies Plan to initiate two pivotal Phase 3 trials for IPF chronic cough starting Q2 2026, running in parallel.

Expand Chronic Cough Development Adaptive Phase 2b trials planned for non-IPF ILD and RCC indications starting second half of 2026.

Complete NDA Supportive Testing Progressing remaining Phase 1 NDA supportive studies, including respiratory safety assessment, targeting completion mid-2026.

Maintain Intellectual Property Focus remains on maintaining, expanding, and protecting proprietary patent portfolio across key territories globally.

同業比較

売上高 (TTM)

NVAX

$1.12B

+64.7%

ARDX

$407.32M

+22.1%

SNDX

$172.35M

+627.8%

粗利益率 (最新四半期)

SNDX

102.3%

-13.9pp

NBTX

100.0%

+0.0pp

IMTX

100.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
TERN	$4.74B	-51.0	-20.0%	0.1%
SYRE	$4.41B	-162.8	-29.4%	0.0%
SNDX	$2.14B	-7.4	-206.6%	65.4%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月6日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし